PBYI Q4 2025 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$76M+27.8% YoY

Gross Profit

$52M69.3% margin

Operating Income

$17M22.6% margin

Net Income

$13M17.7% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

+38.6%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

$21M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$216M

Total Liabilities

$86M

Stockholders' Equity

$130M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$76M	$59M	+27.8%
Gross Profit	$52M	$45M	+15.8%
Operating Income	$17M	$13M	+27.9%
Net Income	$13M	$19M	-30.6%

Revenue Segments

Product

$60M79%

Royalty

$16M21%